| 1347 |
National Cancer Institute |
Html |
null |
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of pancreatic neuroendocrine tumors (islet cell tumors). |
|
|
CLICK HERE |
| 1381 |
National Cancer Institute |
Html |
en |
Skin Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing skin cancer and about research aimed at the prevention of this disease. |
| skin cancer | 0.822138 |
| NMSC lesion reduction | 0.586326 |
| skin cancer reduction | 0.555393 |
| self-reported midday sun | 0.540371 |
| average new lesions | 0.584312 |
| Skin Cancer Prevention | 0.571287 |
| study attrition rates | 0.542607 |
| new actinic keratoses | 0.584773 |
| fewer actinic lesions | 0.603501 |
| skin cancer—a time | 0.536376 |
| daily sunscreen application | 0.747804 |
| poor surrogate endpoint | 0.539998 |
| 6-month post-intervention follow-up | 0.542973 |
| fewer new lesions | 0.602501 |
| solar keratoses | 0.994656 |
| provider-based sun protection | 0.532584 |
| sun protection factor | 0.548485 |
| Australian randomized study | 0.58712 |
| regular sunscreen | 0.624027 |
| sunscreen placebo | 0.612947 |
| UV radiation exposure | 0.5401 |
| clinically normal skin. | 0.54962 |
| SCC prevention trials | 0.561668 |
|
| new solar keratoses | 0.591696 |
| sun-protective behaviors | 0.556779 |
| significantly lower number | 0.53979 |
| chemopreventive agent | 0.53119 |
| invasive skin cancer | 0.584968 |
| community skin cancer | 0.550184 |
| population-based longitudinal study | 0.568978 |
| significantly greater number | 0.537464 |
| placebo group | 0.679758 |
| NMSC incidence rates | 0.595744 |
| Reduce Actinic Cancer | 0.56707 |
| spontaneous regression rate | 0.544682 |
| 4-month clinical trials | 0.540996 |
| randomized controlled trial | 0.576053 |
| new lesions | 0.702948 |
| randomized trials | 0.539994 |
| nicotinamide group | 0.630321 |
| base-cream placebo group | 0.599568 |
| appearance-based behavioral interventions | 0.531285 |
| sun exposure | 0.594318 |
| sunscreen group | 0.779335 |
| NMSC lesions | 0.609075 |
| self-reported sun-protective behaviors | 0.541953 |
|
CLICK HERE |
| 1427 |
National Cancer Institute |
Html |
en |
Cancer Pain (PDQ®)–Patient Version |
Expert-reviewed information summary about pain as a complication of cancer or its treatment. Approaches to the management and treatment of cancer-associated pain are discussed. |
| pain pathway | 0.562753 |
| cancer treatment | 0.530419 |
| opioid doses | 0.512563 |
| certain older patients | 0.494486 |
| blocks pain | 0.560936 |
| PDQ cancer information | 0.578981 |
| Skin pain | 0.59257 |
| pain medicine | 0.620891 |
| pain treatment | 0.60597 |
| different opioid | 0.496343 |
| pain control plan | 0.622009 |
| means mild pain | 0.593227 |
| cancer information summary | 0.53585 |
| bone pain | 0.598741 |
| PDQ Cancer Pain | 0.631355 |
| patients | 0.72567 |
| cancer patients | 0.497501 |
| Poor pain | 0.553511 |
| NCI PDQ cancer | 0.498652 |
| effects | 0.513118 |
| radiation therapy | 0.594681 |
| patients better pain | 0.603263 |
| chronic pain | 0.55423 |
| pain control medicine | 0.611052 |
| new pain | 0.590569 |
|
| breakthrough pain | 0.577542 |
| palliative care | 0.539853 |
| Pain relievers | 0.575317 |
| pain control | 0.678976 |
| Treating Cancer Pain | 0.619773 |
| National Cancer Institute | 0.532557 |
| commonly used opioid | 0.491401 |
| pain relief | 0.639394 |
| cancer pain | 0.765349 |
| older patients | 0.709433 |
| pain | 0.970646 |
| current pain treatments | 0.604816 |
| healthcare team | 0.547409 |
| drugs | 0.511492 |
| opioid treatment | 0.49086 |
| external radiation therapy | 0.506549 |
| intense pain | 0.577346 |
| severe pain | 0.654451 |
| PDQ summary | 0.540695 |
| control pain | 0.601004 |
| pain levels | 0.579761 |
| means moderate pain | 0.593293 |
| pain threshold | 0.556519 |
| means severe pain | 0.59891 |
|
CLICK HERE |
| 1605 |
National Cancer Institute |
Html |
en |
Cervical Cancer Screening (PDQ®)–Patient Version |
Expert-reviewed information summary about tests used to detect or screen for cervical cancer. |
| PDQ Screening | 0.389933 |
| abnormal cells | 0.425615 |
| helpful screening test | 0.401855 |
| treatment | 0.366742 |
| cancer screening methods | 0.422407 |
| Pap test results | 0.472434 |
| ongoing clinical trials | 0.410435 |
| certain positive Pap | 0.459229 |
| screening tests | 0.370134 |
| cervical cancer increases | 0.4511 |
| HPV test lowers | 0.401961 |
| cancer cells | 0.382684 |
| Pap smear | 0.380615 |
| following PDQ summaries | 0.395466 |
| Cancer Information Service | 0.388041 |
| human papillomavirus | 0.366703 |
| PDQ cancer information | 0.504059 |
| false-negative test result | 0.373852 |
| Prevention Editorial Board | 0.401875 |
| National Cancer Institute | 0.462131 |
| clinical trials | 0.549883 |
| cervical changes | 0.387237 |
| Pap tests | 0.380549 |
| false-positive test results | 0.375133 |
|
| cancer information summary | 0.450393 |
| Pap test | 0.755213 |
| cervix | 0.421409 |
| positive Pap test | 0.475496 |
| breast cancer prevention | 0.377745 |
| Cancer screening trials | 0.426144 |
| HPV test | 0.524062 |
| cervical cancer screening | 0.546179 |
| Cancer Care page | 0.38052 |
| cervical cancer | 0.937005 |
| PDQ summary | 0.376855 |
| HPV DNA test | 0.398682 |
| cervical tissue | 0.390487 |
| cancer symptoms | 0.370983 |
| NCI PDQ cancer | 0.416761 |
| HPV infection | 0.382279 |
| cells | 0.465881 |
| tests | 0.403289 |
| cancer information summaries | 0.392344 |
| cervical dysplasia | 0.41859 |
| comprehensive cancer information | 0.393061 |
| HPV infections | 0.396784 |
| women | 0.413929 |
|
CLICK HERE |
| 1647 |
National Cancer Institute |
Html |
en |
Cancer Prevention Overview (PDQ®)–Patient Version |
General information about cancer prevention and descriptions of the concepts used in cancer-specific prevention summaries. |
| cancer treatment | 0.389185 |
| cancer prevention trials | 0.468498 |
| cause cervical cancer | 0.426832 |
| cancer deaths | 0.393998 |
| cancer risk factors | 0.474952 |
| following PDQ summaries | 0.808586 |
| PDQ cancer information | 0.606013 |
| lung cancer | 0.390908 |
| cancer cell | 0.406069 |
| PDQ Cancer Clinical | 0.490906 |
| clinical trials | 0.533549 |
| female colorectal cancer | 0.421435 |
| cancer information summary | 0.495456 |
| risk factors | 0.581677 |
| breast cancer prevention | 0.458936 |
| colorectal cancer | 0.45031 |
| postmenopausal breast cancer | 0.416658 |
| lower risk | 0.405329 |
| cancer patients | 0.386754 |
| cancer risk factor | 0.461133 |
| NCI’s PDQ | 0.406851 |
| NCI PDQ cancer | 0.48445 |
| endometrial cancer | 0.390827 |
| PDQ Screening | 0.394502 |
|
| Cancer prevention | 0.585935 |
| cancer protective factor | 0.422508 |
| thyroid cancer | 0.393113 |
| slightly lower risk | 0.392487 |
| Cancer Information Service | 0.42609 |
| PDQ Cancer Prevention | 0.489242 |
| Prevention Editorial Board | 0.417286 |
| National Cancer Institute | 0.497792 |
| studies | 0.410588 |
| PDQ documents | 0.395881 |
| cancer share | 0.415971 |
| Cancer Prevention Trial | 0.424401 |
| modifiable risk factors | 0.414325 |
| Cancer Care page | 0.410934 |
| PDQ database | 0.399212 |
| breast cancer | 0.502143 |
| following types | 0.420925 |
| PDQ summary | 0.45002 |
| prostate cancer | 0.399534 |
| cancer clinical trials | 0.466733 |
| cancer information summaries | 0.43798 |
| comprehensive cancer information | 0.431575 |
| cancer | 0.932793 |
| risk | 0.651792 |
|
CLICK HERE |
| 1788 |
National Cancer Institute |
Html |
es |
Sofocos y sudores nocturnos (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de las causas y el tratamiento de los sofocos y sudores nocturnosen los pacientes de cáncer. |
| Visuals Online | 0.455251 |
| sudor ayuda | 0.533401 |
| Physician Data Query | 0.790217 |
| cardo lechero | 0.494962 |
| siguientes medidas | 0.498906 |
| sección sÃntomas vasomotores | 0.544529 |
| hierba sonajero | 0.494475 |
| terapeuta ayuda | 0.487201 |
|
| estudios piloto | 0.477833 |
| PDQ Sofocos | 0.908716 |
| National Cancer Institute | 0.497344 |
| siguientes riesgos | 0.46265 |
| escasa información | 0.45999 |
| frecuencia respiratoria | 0.494154 |
| Instituto Nacional | 0.581027 |
|
CLICK HERE |
| 1940 |
National Cancer Institute |
Html |
es |
La espiritualidad en el tratamiento del cáncer (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca de la influencia que tiene la espiritualidad y la religión en las personas que tienen cáncer. Se discuten varios métodos sobre manejo e intervención. |
| enfermos ayuda | 0.452293 |
| La espiritualidad | 0.924579 |
| términos espiritualidad | 0.486044 |
| siguientes aspectos | 0.444194 |
| Physician Data Query | 0.534722 |
|
| National Cancer Institute | 0.427034 |
| siguientes riesgos | 0.41834 |
| libre uso | 0.416111 |
| siguientes maneras | 0.524006 |
| Instituto Nacional | 0.45946 |
|
CLICK HERE |
| 2016 |
National Cancer Institute |
Html |
es |
Aspectos generales de la prevención del cáncer (PDQ®)–Versión para pacientes |
Información general sobre la prevención del cáncer y descripciones de conceptos usados en sumarios específicos sobre la prevención del cáncer. |
| radiación ionizante causa | 0.460647 |
| cientÃficos estudian | 0.489171 |
| Vitamina B12 | 0.441748 |
| principales factores | 0.444309 |
| altos costos | 0.431231 |
| siguientes tipos | 0.443767 |
| Vitamina C | 0.440272 |
| determinadas sustancias | 0.434346 |
| bacteria helicobacter | 0.42962 |
| Vitamina B6 | 0.441932 |
| Clinical Trials Registry | 0.438953 |
| vitamina d | 0.4813 |
| National Cancer Institute | 0.429703 |
| siguientes riesgos | 0.428971 |
| alto contenido | 0.463103 |
| ligera disminución | 0.41989 |
| vitamina e | 0.538039 |
| Instituto Nacional | 0.447408 |
|
| OmegA-3 TriaL | 0.424385 |
| antecedentes familiares | 0.422212 |
| sumario prevención | 0.489845 |
| Cancer Prevention Trial | 0.437168 |
| hepatitis b | 0.427578 |
| Physician Data Query | 0.503692 |
| células tumorales benignas | 0.462584 |
| Radiación ultravioleta | 0.43604 |
| Leucemia mielógena aguda | 0.449074 |
| Estados Unidos | 0.563042 |
| prevención revisa | 0.457445 |
| Physician´s Health Study | 0.436091 |
| cabo estudios | 0.425211 |
| PDQ Prevención | 0.699792 |
| siguientes vitaminas | 0.436186 |
| siguientes medicamentos | 0.44035 |
| Gas radón | 0.426739 |
| PDQ Aspectos | 0.466808 |
|
CLICK HERE |
| 2073 |
National Cancer Institute |
Html |
es |
Biopsia de ganglio linfático centinela |
Describe el procedimiento de biopsia de ganglio linfático centinela, su uso para determinar la extensión, o estadio, del cáncer en el cuerpo, y los resultados de investigación sobre el uso de este tipo de biopsia en cáncer de seno y melanoma. |
| Surgical Adjuvant Breast | 0.600625 |
| Lancet Oncology | 0.600394 |
| falsa sensación | 0.600322 |
| American Medical Association | 0.600457 |
| Hunt KK | 0.600275 |
| excelente resultado | 0.600374 |
| Anderson SJ | 0.600281 |
| ganglio linfático centinela | 0.999164 |
| Selective Lymphadenectomy Trial | 0.600594 |
| Bowel Project | 0.600314 |
| células inmunitarias llamadas | 0.601282 |
| Julian TB | 0.600295 |
| Ballman KV | 0.60032 |
| linfocitos b | 0.600438 |
| Giuliano AE | 0.600304 |
| rara vez | 0.60032 |
| ganglios linfáticos centinelas | 0.613287 |
| sentinel node metastasis | 0.600629 |
| axillary dissection | 0.600834 |
| Instituto Nacional | 0.602213 |
|
| Krag DN | 0.600307 |
| Lyman GH | 0.600292 |
| Axillary dissection vs | 0.600551 |
| fase iii | 0.601556 |
| Surgeons Oncology Group | 0.600619 |
| ganglio centinela | 0.636993 |
| ecografÃa rutinaria | 0.600317 |
| pequeña incisión | 0.600338 |
| overall survival findings | 0.600577 |
| PubMed Abstract | 0.601839 |
| sentinel lymph | 0.601172 |
| Silbermins D | 0.600275 |
| with invasive breast | 0.600626 |
| Lymphatic mapping | 0.600313 |
| patients with | 0.600887 |
| linfadenectomÃa axilar | 0.605014 |
| Instituto Oncológico John | 0.60052 |
| Clinical Oncology | 0.600393 |
| NSABP B-32 | 0.600293 |
|
CLICK HERE |
| 16827 |
National Cancer Institute |
Html |
en |
Structural Genomics Research |
NCI's Center for Cancer Genomics uses structural cancer genomics to identify genomic alterations that contribute to cancer growth, metastasis, and recurrence. |
| Genome Research Institute | 0.728945 |
| certain childhood cancers | 0.712528 |
| dramatically positive responses | 0.673976 |
| cancer research community | 0.755287 |
| genomic profiles | 0.642832 |
| Cancer Treatment | 0.810342 |
| ovarian cancers | 0.656249 |
| lung cancer | 0.670167 |
| Cancer Therapy Evaluation | 0.727719 |
| active CGCI projects | 0.698291 |
| National Clinical Trials | 0.691331 |
| access TARGET data | 0.715985 |
| acute myeloid leukemia | 0.673618 |
| particular drug therapies | 0.672703 |
| CGCI data matrix | 0.717543 |
| comprehensive study | 0.628252 |
| National Cancer Institute | 0.740247 |
| Molecular Characterization Project | 0.703185 |
| potential therapeutic targets | 0.68353 |
| Genome Characterization Pipeline | 0.731626 |
| pediatric cancers | 0.650887 |
| comprehensive genomic approaches | 0.718344 |
| Exceptional Responders Initiative | 0.693832 |
| NCI’s Division | 0.72848 |
|
| genomic alterations | 0.6735 |
| download data | 0.627727 |
| structural genomics research | 0.918362 |
| CCG | 0.743836 |
| key genomic changes | 0.728492 |
| NCI-sponsored clinical trials | 0.687692 |
| cancer patients | 0.672659 |
| Genomic Data Commons | 0.781309 |
| NCI Community Oncology | 0.716524 |
| breast cancer | 0.651548 |
| cancer types | 0.669231 |
| Cancer Genome Atlas | 0.81731 |
| TCGA dataset | 0.680049 |
| different types | 0.707662 |
| oncogenic alterations | 0.665162 |
| renal cell carcinoma | 0.68003 |
| medicine clinical trial | 0.701003 |
| large B-cell lymphoma | 0.698622 |
| acute lymphoblastic leukemia | 0.672538 |
| Lymphoma Genome Sequencing | 0.742417 |
| cancer biology | 0.685502 |
| oncogenic process | 0.62839 |
| TCGA data | 0.706048 |
|
CLICK HERE |